<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kountourakis, P.</style></author><author><style face="normal" font="default" size="100%">Psyrri, A.</style></author><author><style face="normal" font="default" size="100%">Scorilas, A.</style></author><author><style face="normal" font="default" size="100%">Markakis, S.</style></author><author><style face="normal" font="default" size="100%">Kowaiski, D.</style></author><author><style face="normal" font="default" size="100%">Camp, R.L.</style></author><author><style face="normal" font="default" size="100%">Diamandis, E.P.</style></author><author><style face="normal" font="default" size="100%">Dimopoulos, M.A.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Expression and prognostic significance of kallikrein-related peptidase 8 protein levels in advanced ovarian cancer by using automated quantitative analysis</style></title><secondary-title><style face="normal" font="default" size="100%">Thrombosis and Haemostasis</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Advanced ovarian cancer</style></keyword><keyword><style  face="normal" font="default" size="100%">AQUA</style></keyword><keyword><style  face="normal" font="default" size="100%">Kallikrein-related peptidase 8</style></keyword><keyword><style  face="normal" font="default" size="100%">Prognosis</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2009</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2009</style></date></pub-dates></dates><urls><web-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-62549103358&amp;doi=10.1160%2fTH08-01-0052&amp;partnerID=40&amp;md5=999265a01129d52481c3b42b5d53a84c</style></url></web-urls></urls><volume><style face="normal" font="default" size="100%">101</style></volume><pages><style face="normal" font="default" size="100%">541 - 546</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">Kallikrein-related peptidases, a subgroup of the serine protease enzyme family, are considered to be important prognostic biomarkers in cancer. In this study we sought to determine the prognostic value of kallikrein-related peptidase 8 (KLK8,hK8,KLK-8) in ovarian cancer using a novel method of compartmentalised in situ protein analysis.A tissue array composed of 150 advanced stage ovarian cancers, uniformly treated with surgical debulking followed by platinum-paclitaxel combination chemotherapy,was constructed. For the evaluation of kallikrein-related peptidase 8 protein expression, we used an immunofluorescence-based method of automated in situ quantitative protein analysis (AQUA). Mean follow-up time of the cohort was 34.35 months. One hundred twenty-six of 150 cases had sufficient tissue for AQUA analysis.There were significant correlations between tumour mask KLK8 protein expression levels and clinicopathological variables, including grade (p=0.0011), residual disease (p=0.0063) and clinical response to chemotherapy(p=0.0346). In univariate survival analysis there was a significant correlation between KLK8 tumour mask expression and five years progression-free survival, meanwhile it was not associated with five-year overall survival (p =0.0694). Specifically, low KLK8 expression correlated with better outcome (top vs. bottom quartile, p=0.0319). In multivariate survival analysis, adjusting for well-characterised prognostic variables, tumour KLK8 expression level retained its prognostic significance for progression-free survival (95%Cl: 0.341-1.027, p=0.045). The possibility that KLK8 may be a suitable candidate as a diagnostic and prognostic marker warrants further investigation. © 2009 Schattauer GmbH.</style></abstract><issue><style face="normal" font="default" size="100%">3</style></issue><notes><style face="normal" font="default" size="100%">Cited By :16Export Date: 21 February 2017</style></notes></record></records></xml>